Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France, April 5, 2024, 10:00 p.m. CEST – Abivax SA ((Euronext Paris &amp, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d'Enregistrement Un ...

Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and EUR 223.3M initial public offering on the Nasdaq Global MarketSufficient funds to finance operations into Q4 2025, including through the announcement of top-line data from the Phase 3 ABTECT induction trials of obefazimod in ulcerative colitis (UC)Implementation of U.S. and European operational infrastructure to progr ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Sofinnova Investments, a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor. In this role, he will be advising Sofinnova’s portfolio companies on corporate and financial strategy. Mr. Ignelzi brings to Sofinnova over two decades of financial leadership experience in the biotech and pharmaceuticals sectors. He is currently Chief Financial Officer at Rapport Therapeutics, a clinical-stage biotechnol ...

Abivax appoints Ana Sharma as Vice President, Global Head of Quality PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality. Ms. Sharma brings over 20 years of experien ...

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn's disease Obefazimod Crohn's Disease (CD) IND filed with the FDA in December 2023 and cleared to proceedIn alignment with FDA feedback, Abivax to modify CD trial design and conduct dose ranging Phase 2b clinical trialStart of patient enrollment planned for Q3 202412-week induction data read-out expected in 2H 2026 PARIS, France, February 2, 2024, 8:30 a.m. CET – Abivax SA ((Euronext Paris &amp, ...

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024 PARIS, France, January 24, 2024, 8:30 a.m. CET – Abivax SA ((Euronext Paris &amp, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammato ...

Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in moderately to severely active ulcerative colitis (UC) Formal process evaluating oral and injectable combination therapy candidates with obefazimod in UC has commenced; preclinical data to support decision-making on combination agent expected in 2H 2024Top-line data from long-term extension trial with 25mg obefazimod o ...

Abivax 2024 Financial Communication Calendar PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA ((Euronext Paris &amp, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today publishes its 2024 financial communication calendar. Tuesday, April 2, 20242023 Annual Business and Financial Report (as of Decemb ...